Overview

An Open Label Dose Escalation Study Of E7080

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Lenvatinib